Inotuzumab (powder)
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin. Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4]. x
Product Specifications
CAS Number
1660159-36-3
Product Name Alternative
Humanized Anti-CD22 Recombinant Antibody (powder)
UNSPSC
12352203
Target
ADC Antibody; Apoptosis; CD22
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Immunology/Inflammation
Field of Research
Cancer
Smiles
[Inotuzumab(powder)]
Molecular Weight
(146.48 kDa)
References & Citations
[1]Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.|[2]Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3 (1) :96-104. |[3]Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137 (19) :2657-2661.|[4]Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18 (5) :1101-1116.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC473168-500 1x 500 µL
GRP94 / HSP90B1 (Glucose-Regulated Protein 94) (Endoplasmic Reticulum Marker) (HSP90B1/3168R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TP314781M 100 µg
Stabilin 2 (STAB2) (NM_017564) Human Recombinant Protein
Sign In for Pricing
View Details 
